A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (ASH 2025) - Nov 4, 2025 - Abstract #abs25-7361; 5822; Pres time: Dec 8, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Treatment with GR1803 was well tolerated with excellent anti-myeloma activity, especially inpatients with EMM. GR1803 is expected to improve the prognosis of patients with RRMM.Acknowledgments: This study was funded by Chongqing Genrix Biopharmaceutical Co., Ltd."
Clinical • Monotherapy • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases
|
|
Min Yang1; Yang Liang2; Guorong Wang3; Baijun Fang4; Luqun Wang5; Songfu Jiang6; Yafei Wang7; Heng Mei8; Wei Yang9; Yanjuan He10; Wei Wang11,12; Haichao Zhang11,12; Houguo Wang11,12; Jie Jin1; Wenming Chen3
|